Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

"Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma

NCT: NCT06988020 · RECRUITING

NCT IDNCT06988020
StatusRECRUITING
Start Date2025-04-22
Completion2027-11

Brief Summary

Recent work has confirmed the diagnostic performance of pseudo-CT sequences for detecting osteolytic lesions. Their integration into whole body MRI (WB MRI) could transform the diagnostic approach to MM, by allowing a combined assessment of bone marrow involvement, tissue viability and osteolysis, during a single non-irradiating imaging examination. Since the preliminary work mentioned above, optimizations have been made to the pseudo-CT sequences, including the addition of deep learning (correcting noise in the images) and the correction of chemical shift artifact (linked to the coexistence of hydrated tissue and fatty tissue), which carry real hope of improving their diagnostic potential and accuracy.

Frequently Asked Questions

What is "Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma?

"Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma is a clinical trial registered under NCT06988020. Current status: RECRUITING.

What is the status of NCT06988020?

The current status of NCT06988020 ("Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma) is: RECRUITING.

When did "Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma start?

"Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma started on 2025-04-22.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.